MTM Laboratories (Germany) a commercial-stage molecular diagnostics company focused on cervical cancer, closed on a $9M Series C financing bringing the total round to $65M. Participants include Gilde Healthcare Partners, LBBW Venture Capital, HBM BioVentures and HBM BioCapital.